Otilimab
Unassigned
New Medicines
Moderate-severe rheumatoid arthritis (RA), unresponsive to methotrexate
Information
New molecular entry
GlaxoSmithKline
GlaxoSmithKline
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that mediates immune mediated diseases, including RA
One study in the UK found the population minimum prevalence of RA to be 1.16% in women and 0.44% in men. The incidence of the condition is low, with around 1.5 men and 3.6 women developing RA per 10,000 people per year [3].
Moderate-severe rheumatoid arthritis (RA), unresponsive to methotrexate
Subcutaneous injection